This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol 29, 467–468 (2011). https://doi.org/10.1038/nbt0611-467
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0611-467
This article is cited by
-
Efficacy and safety of jakinibs in rheumatoid arthritis: a systematic review and meta-analysis
Clinical Rheumatology (2021)
-
Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS)
Journal of Clinical Immunology (2015)
-
Activation of Nicotinic Receptors Inhibits TNF-α-Induced Production of Pro-inflammatory Mediators Through the JAK2/STAT3 Signaling Pathway in Fibroblast-Like Synoviocytes
Inflammation (2015)
-
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market
Nature Biotechnology (2013)
-
Tofacitinib, a Janus Kinase Inhibitor Demonstrates Efficacy in an IL-15 Transgenic Mouse Model that Recapitulates Pathologic Manifestations of Celiac Disease
Journal of Clinical Immunology (2013)